GBPP 2025 Global Bio Pharma Plaza Overview
GBPP (Global Bio Pharma Plaza) is one of KOTRA's largest export consultation programs dedicated to the bio and pharmaceutical industries. It functions as a B2B matching platform spanning biosimilars, active pharmaceutical ingredients (APIs), finished pharmaceuticals, medical devices, and CMO/CDMO services, connecting Korean suppliers with pharmaceutical and biotech buyers worldwide.
In 2025, GBPP is expected to host more than 200 Korean bio and pharmaceutical companies and invite over 400 overseas buyers from 35 countries, generating more than 2,500 specialized business consultations. Bangladesh represents a growing pharmaceutical market, with the sector accounting for roughly 1.2% of GDP, and more than 10 Bangladeshi buyers joining the event each year.
Program Structure
GBPP 2025 is organized around five tracks: export consultations, corporate IR sessions, regulatory and licensing conferences, factory visits, and a networking reception. Because pharmaceutical transactions require careful regulatory alignment, the regulatory sessions are especially important, giving participants direct insight into approval and compliance requirements in target markets.
| Day | Program | Audience | Scale | Key Focus |
|---|---|---|---|---|
| Day 1 | B2B Export Consultations | All sectors | 1,000+ | Biosimilars, APIs, finished drugs |
| Day 1 | Regulatory Conference | Experts | 4 sessions | Country approvals and GMP |
| Day 2 | B2B Export Consultations | CMO/CDMO | 800+ | Contract manufacturing and tech transfer |
| Day 2 | Corporate IR | Investors | 20 firms | Pipeline presentations |
| Day 3 | Factory Visits | Buyers | 5 sites | GMP facility inspections |
| Day 3 | Networking | All participants | 200 | Reception and MOUs |
Consultation Analysis by Segment
Bangladesh's Pharmaceutical Market and GBPP
Bangladesh's pharmaceutical industry is valued at about USD 3.5 billion annually and supplies roughly 97% of domestic demand through local production. However, the country remains import-dependent in higher-value areas such as biosimilars, advanced APIs, and sophisticated diagnostic equipment, which creates practical entry points for Korean suppliers. Bangladeshi buyers attending GBPP are typically interested in API sourcing, CMO partnerships, and distribution of diagnostic products.
| Segment | No. of Buyers | Consultations | Deals Closed | Key Interests |
|---|---|---|---|---|
| APIs | 4 | 40 | 8 | Antibiotic and antipyretic raw materials |
| Biosimilars | 3 | 25 | 4 | Insulin and antibody therapeutics |
| CMO/CDMO | 2 | 15 | 2 | Contract manufacturing and tech transfer |
| Diagnostics and Medical Devices | 3 | 20 | 3 | Diagnostic kits and monitoring tools |
| Total | 12 | 100 | 17 | Overall deal rate: 17% |
Participation Strategy for Companies
GBPP stands apart from general trade fairs because it is structured around the high-value, regulation-intensive bio and pharmaceutical industries. Its core strength lies in a three-step sequence: understanding approval requirements through regulatory sessions, negotiating concrete business terms in B2B meetings, and building trust through factory visits. Bangladesh's pharmaceutical market, valued at roughly USD 3.5 billion and expanding at around 10% annually, offers growing opportunities for Korean companies in APIs, biosimilars, and CMO partnerships. For firms assessing market entry, GBPP 2025 can serve as a practical first gateway into Bangladesh's healthcare manufacturing ecosystem.